Table 3 Best overall response in the total BID dosage group.

From: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

Total BID dosage group

 

Overall efficacy-evaluable population (n = 77)

EOC efficacy-evaluable population (n = 51)

Best overall response, n (%)

 Complete response

4 (5.2)

4 (7.8)

 Partial response

17 (22.1)

17 (33.3)

 Stable disease

37 (48.1)

24 (47.1)

 Progressive disease

11 (14.3)

2 (3.9)

 Not evaluable

1 (1.3)

1 (2.0)

 Not assesseda

7 (9.1)

3 (5.9)

Objective response rate, % (95% CI)b

27.3 (17.7–38.6)

41.2 (27.6–55.8)

Clinical benefit rate, % (95% CI)c

39.0 (28.1–50.8)

54.9 (40.3–68.9)

Disease control rate, % (95% CI)d

75.3 (64.2–84.4)

88.2 (76.1–95.6)

  1. BID twice a day, CI confidence interval, EOC epithelial ovarian cancer.
  2. aPatients in the efficacy-evaluable analysis set who discontinued before postbaseline tumour assessment due to disease progression or death are listed with a best overall response of not assessed.
  3. bObjective response rate = complete response + partial response.
  4. cClinical benefit rate = complete response, partial response, or stable disease lasting at least 24 weeks without disease progression.
  5. dDisease control rate = complete response, partial response, or stable disease as confirmed best response.
Back to article page